Talking Early 2013 U.S. MIPO launch so to me that means a Late November PADUFA Date. (2+6 from March Filing date)
But The EU will be in late 2012 and its a much larger patient population market.
Mipo launch will be a factor in the revaluation of all Antisense based drugs. OGXI sells at a big discount because its drug development platform is Antisense Technology.
Early Jan/13 per CC
P1/P2 pipeline is moving forward and another GSK or Biogen type partnership is coming this year. The more antisense platform validation that the street sees the better for OGXI.
ISIS got a CC bounce today.
I see the stock heading higher over the next year as the early P1/P2 pipeline matures and MIPO gets approved and launched in both the EU and U.S. markets.
When, not if, Antisense platform catches fire OGXI will trade at its real value.